October 2025 in “Transactions on Materials Biotechnology and Life Sciences” This study reviews the mechanisms and recent findings of immunotherapies for NSCLC, highlighting their potential to improve treatment outcomes and reduce side effects compared to traditional therapies.
1 citations
,
October 2022 in “Дерматовенерология Косметология” This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.
13 citations
,
August 2018 in “Life sciences” This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.
2 citations
,
May 2011 in “Journal of Clinical Oncology” This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.
March 2018 in “International journal of basic and clinical pharmacology” This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.